O104
奥美拉唑
≥98% (HPLC), solid, gastric secretion inhibitor
别名:
5-甲氧基-2 - [[（4-甲氧基-3，5-二甲基-2-吡啶基）甲基]亚磺酰基] -1H-苯并咪唑, Antra, Losec
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H19N3O3S
化学文摘社编号:
分子量:
345.42
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
奥美拉唑, solid
SMILES string
COc1ccc2[nH]c(nc2c1)S(=O)Cc3ncc(C)c(OC)c3C
InChI
1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
InChI key
SUBDBMMJDZJVOS-UHFFFAOYSA-N
form
solid
color
white
solubility
H2O: 0.5 mg/mL, DMSO: >19 mg/mL, ethanol: 4.5 mg/mL
originator
AstraZeneca
storage temp.
2-8°C
Quality Level
Gene Information
human ... ABCB1(5243), ATP4A(495), ATP4B(496), CYP1A2(1544)
正在寻找类似产品? 访问 产品对比指南
General description
奥美拉唑是一种苯并咪唑衍生物，弱碱性，并且具有亲脂性。该化合物对pH敏感，在低pH下不以其原始形式存在。
Application
奥美拉唑已在Dulbecco′改良eagle′s培养基（无血清）中用作非典型细胞色素P450（CYP）1A2诱导剂，以研究诱导剂对人肝细胞CYP活性的影响，并与其他经典的芳烃受体配体进行比较。
Biochem/physiol Actions
奥美拉唑可与质子泵发生共价结合（H+，K+-ATPase），并抑制胃分泌。它可用于改善消化性食管炎、十二指肠和胃溃疡的影响。由于其效率更高，因此奥美拉唑更优于组胺H2受体和雷尼替丁的拮抗剂。它也可用于治疗Zollinger-Ellison综合征。
Features and Benefits
该化合物是ADME Tox研究的推荐产品。点击此处查看更多特色 ADME Tox 产品。在sigma.com/discover-bsm 上了解有关生物活性小分子在其他研究领域的更多信息。
该化合物由AstraZeneca开发。要浏览其他药物开发的化合物和已批准药物/候选药物的列表，请单击此处。
Disclaimer
吸湿，光敏
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 2 - Skin Sens. 1
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Un-Ho Jin et al.
Cancers, 12(8) (2020-08-01)
Background: The aryl hydrocarbon receptor (AhR) is expressed in gliomas and the highest staining is observed in glioblastomas. A recent study showed that the AhR exhibited tumor suppressor-like activity in established and patient-derived glioblastoma cells and genomic analysis showed that
Profiling the hepatic effects of flutamide in rats: A microarray comparison with classical AhR ligands and atypical CYP1A inducers
Coe KJ, et al.
Drug Metabolism and Disposition (2006)
S E Attwood et al.
Alimentary pharmacology & therapeutics, 41(11), 1162-1174 (2015-04-11)
Control of chronic gastro-oesophageal reflux disease may be achieved either by anti-reflux surgery (ARS) or by long-term medical therapy with proton pump inhibitors (PPIs). The primary efficacy results of the SOPRAN study, comparing long-term omeprazole use with open ARS, and
Omeprazole
S. Holt and C. W. Howden
Drugs, 36(4), 385?393-385?393 (1991)
The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes
Hellum BH, et al.
Basic and clinical neuroscience, 100(1), 23-30 (2007)
商品
Discover Bioactive Small Molecules for ADME/Tox
相关内容
Datasheet
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持